Cystic Fibrosis in Arab Families: A Disease Diagnosed Too Late

What Is Cystic Fibrosis and What Does It Do to the Body?

Cystic fibrosis is caused by a defect in the CFTR gene, which controls how salt and fluid move across cell membranes. When this gene is faulty, cells produce thick sticky mucus instead of thin watery secretions. That mucus builds up in the lungs, pancreas, intestines and other organs.

In the lungs, thick mucus creates an ideal environment for bacteria. Infections accumulate and scar the airways over years. In the digestive system, mucus blocks the ducts that carry pancreatic enzymes to the intestine, so food is not properly digested or absorbed. The result is poor weight gain despite a good appetite.

CF affects almost every organ system. The sinuses, liver, kidneys and reproductive tract are all involved. But it is the lungs that drive the severity and long-term outlook of the disease.

Why Is CF So Often Diagnosed Late in the Arab Region?

A 2014 study published in the Journal of Advanced Research at a major Egyptian referral centre found that the average age of diagnosis was over two years, and that many children arrived with advanced complications after being treated for other conditions. Lung function that is lost to repeated uncontrolled infections cannot be recovered. The widespread assumption among clinicians that CF is a rare Western disease is the primary driver of this delay.

In reality, genetic studies in Lebanon, Egypt and the Gulf have documented CFTR mutations at higher rates than expected in Arab populations. A 1997 Lebanese study identified a spectrum of CFTR mutations that differs from the European pattern, meaning that standard European-designed screening panels can miss Arab CF cases entirely. A 2007 Egyptian study of children with difficult-to-treat respiratory illness found CF among them at a rate that could not be explained by chance alone.

The early symptoms of CF are also non-specific, and this is where the delay compounds. A persistent cough is attributed to asthma. Repeated chest infections are treated course by course with antibiotics without seeking the underlying cause. Poor weight gain is blamed on diet or poverty. A child can pass through years of incorrect diagnoses before the right answer is reached, by which time significant irreversible lung damage may already have occurred. When a clinician does consider CF, the diagnosis can usually be confirmed or excluded within weeks, which is why raising the suspicion is the most valuable step.

Which Signs Should Alert You?

The easiest sign to detect at home is a strongly salty taste on the baby's skin when kissed, or white salt crystals visible on the skin in hot weather. This observation is almost unique to CF and should prompt immediate medical attention.

In the airways: a chronic cough that worsens with exercise, wheezing, and chest infections requiring antibiotics more than twice a year. In the digestive system: abnormally large, greasy, foul-smelling stools, constant bloating, and failure to gain weight despite eating well.

In newborns, severe constipation or intestinal obstruction in the first days of life may be the first clue. In older children, the fingertips and toes may become rounded and bulging (called clubbing) because of chronic low oxygen. Nasal polyps appearing in a young child are also a red flag.

How Is Cystic Fibrosis Diagnosed?

The gold standard test is the sweat chloride test (also called the sweat test). A small device placed on the skin stimulates sweat production using a harmless low-level electrical current. The chloride content of the sweat is then measured. In people with CF, the faulty CFTR gene fails to return chloride to the cells, so it is excreted in sweat at abnormally high concentrations.

A sweat chloride below 30 mmol/L is normal. Between 30 and 59 is borderline and needs repeat testing. A result of 60 mmol/L or above is diagnostic of CF. The test should be repeated at least twice to confirm. It is safe and painless, and can be performed from two weeks of age.

Genetic testing looks for known mutations in the CFTR gene and can confirm the diagnosis and identify which specific mutations a child carries. Because the Arab spectrum of CFTR mutations differs from Western panels, genetic testing should be interpreted alongside the sweat test rather than replacing it.

Why Heat Is an Extra Danger for CF Patients in This Region

People with CF lose far more salt in their sweat than healthy people. In a temperate climate this can usually be compensated through food and hydration. In the summer heat of the Gulf, Iraq, Egypt and the Levant, where temperatures regularly exceed 40 degrees Celsius, the salt loss becomes genuinely dangerous and can lead to severe dehydration and circulatory collapse.

A child with CF may be the first to overheat in a group, show intense thirst out of proportion to the situation, or collapse during outdoor activity. These are not signs of weakness. They are a direct consequence of the biology of the disease.

Patients and families should tell their specialist doctor before travelling to hot regions or when summer begins, so that salt supplementation and hydration plans can be adjusted accordingly. This is a practical and important part of regional CF management that is not always highlighted in materials written for cooler climates.

What Does Daily Management Look Like?

CF has no cure in the conventional sense, though the newer CFTR modulator drugs are the closest thing we have for patients with certain mutations. These modulators correct the faulty protein that the CFTR gene produces rather than just treating its effects, and they have transformed outcomes for patients with some mutation types. For everyone else, consistent daily management turns CF from an acute crisis into a manageable chronic condition. That management has several non-negotiable pillars.

Airway clearance therapy is done every day, usually morning and evening. It involves positioning techniques or oscillating devices that physically shake mucus loose from the airways so it can be coughed out. Skipping these sessions allows mucus to build up and infections to take hold. Pancreatic enzyme replacement capsules must be taken with every meal and any fatty snack, because without them the body cannot absorb fats, proteins or fat-soluble vitamins from food. The dose is adjusted based on the fat content of each meal, which families learn to estimate over time. High-calorie eating is not a choice but a medical requirement: people with CF need significantly more energy than average to compensate for poor absorption and the metabolic cost of fighting chronic infection. Malnutrition in CF directly worsens lung function, so weight monitoring at every clinic visit is taken as seriously as breathing tests.

Inhaled medications, including mucolytics that thin the mucus and preventive or rotating courses of antibiotics in some patients, are part of the daily routine for many. Vitamin supplements, particularly fat-soluble vitamins A, D, E and K, are needed because the blocked pancreatic ducts prevent normal absorption of these from food. The exact regimen is set by the specialist and adjusted over time based on lung function measurements, sputum culture results and the child's growth.

CF, Fertility and Family Planning

More than 97 percent of men with CF are infertile because the vas deferens, the tube that carries sperm, is either blocked or absent. They do produce sperm, but it cannot exit. Biological fatherhood is possible through sperm extraction techniques combined with in vitro fertilisation, but this requires specialist fertility services.

Women with CF have reduced fertility but can conceive naturally. Pregnancy places significant additional demands on the lungs and requires very close specialist monitoring throughout. Outcomes have improved greatly as CF management has improved, but pregnancy in CF is high risk and must be planned carefully.

The most important step for any person with CF considering having children is genetic counselling, and testing the partner for CFTR carrier status. If a person with CF partners with a carrier, each child has a 50 percent chance of having CF. A non-carrier partner means all children will be carriers but not affected.

When Should You Go to the Emergency Department?

Some CF situations become genuine emergencies. Families should know these signs, because delay in a crisis can be life-threatening. It helps to identify a specialist centre in advance and make sure the emergency team there knows your child's case, so that decisions are made by people familiar with CF rather than treating it as an ordinary chest infection.

Between acute episodes, the goal is to prevent crises by keeping to the daily treatment routine. Any worsening compared to the baseline, even gradual, should be reported to the specialist promptly rather than waiting for the next scheduled appointment.

Newborn Screening: Does Your Country Test for CF at Birth?

In many Western countries, CF is included in the newborn heel-prick screen done in the first days of life. This allows treatment to begin before symptoms appear, which dramatically improves outcomes. In most Arab countries, routine newborn CF screening is not yet part of national programmes, though some major hospitals in Saudi Arabia and the UAE offer it.

In the absence of routine screening, symptom recognition is the only path to early diagnosis. If your family has a history of CF, or if a previous child died of unexplained respiratory disease, tell the paediatrician at birth so that early sweat testing can be arranged.

Families where consanguineous marriage is common should consider pre-marital or pre-conception genetic carrier testing. Knowing both partners are carriers before pregnancy allows informed decision-making rather than a crisis diagnosis after a child is born ill.

Sources

• El-Falaki MM, Shahin WA, El-Basha NR et al: Profile of cystic fibrosis in a single referral center in Egypt, Journal of advanced research, 2014
• Naguib ML, Schrijver I, Gardner P et al: Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2007
• Desgeorges M, Megarbané A, Guittard C et al: Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities, Human genetics, 1997
• Shafiq I, Shabeer S, Uzbeck MH et al: Genetic and Clinical Demographics of Adult Cystic Fibrosis Patients in a Middle Eastern Population, Turkish thoracic journal, 2021
• Al-Haggar M, Osman E, Eid AR et al: Screening for the Most Common Mutations of CFTR Gene among Egyptian Children with Difficult-to-Treat Asthma, Journal of pediatric genetics, 2020
• Cystic Fibrosis Foundation: About Cystic Fibrosis, clinical overview and sweat test standards